Christoph B. Olivier,Marius Wessinger/LinkedIn
Mar 13, 2026, 20:11
Christoph B. Olivier: New Research from Marius Wessinger on Predicting Therapy Success After Pulmonary Embolism
Christoph B. Olivier, Head of the Clinical Trials Unit, UHZ Freiburg, shared RPTH Journal‘s post on LinkedIn, adding:
”As the Principal Investigator of this study, Marius Wessinger is sharing new insights on ‘Hemostatic Profiling of Patients after Pulmonary Embolism to Predict Success of Different Therapy Options.’
His work focuses on leveraging TEG analysis to assess hemostatic profiles, aiming to provide more personalized and efficient therapy paths for patients at intermediate-risk.
It is inspiring to see how our team’s dedication translates into clinical evidence that could improve patient outcomes.
Great job, Marius!”
Stay updated with Hemostasis Today.
-
Mar 13, 2026, 19:53Wolfgang Miesbach Announces the New English Edition of “Gene Therapy Concepts in the Treatment of Haemophilia”
-
Mar 13, 2026, 17:21Emmanuel J Favaloro: Acquired Hemostasis Disorders Featured in New Issue of Seminars in Thrombosis and Hemostasis
-
Mar 13, 2026, 17:17Paolo Zamboni: New Insights from Australia on Jugular and Azygous Vein Chronic Obstruction
-
Mar 13, 2026, 17:06Srishti Goyal: Can Thalassemia Major Be Prevented?
-
Mar 13, 2026, 16:59Tagreed Alkaltham: Preventing the Risk of Transfusion Reactions Before They Occur
-
Mar 13, 2026, 16:52Giuseppe Lippi: New Insights Into Antiphospholipid Antibodies and Cardiovascular Thrombosis
-
Mar 13, 2026, 16:51Ahmet Dirican: Apixaban vs Rivaroxaban in Acute VTE
-
Mar 13, 2026, 16:47Sinju Thomas: Combined Red Cell and Plasma Exchange for Severe FES in Sickle Cell Disease
-
Mar 13, 2026, 16:44Michael Makris: Lower Bleeding Risk With Apixaban vs Rivaroxaban in Acute Venous Thrombosis